Effect of Safoof-e-Ziabetus in the management of Ziabetus Shakri ( Type 2 Diabetes Mellitus.

Clinical Evaluation of the Efficacy of Safoof-e-Ziabetus- A Polyherbal Unani Formulation in the Management of Ziabetus Shakri (Type 2 Diabetes Mellitus)-A Randomised, Single Blind,Standard Controlled Clinical Trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040327

Enrollment

Registered

2022-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Powdered Compound Unani drug,Safoof-e-Ziabetus-consisting of six ingredients as: 1.GurmarButi (GymnemaSylvestris R.Br.) 2.Gilo(TinosporaCordifolia)

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any gender (Male,Female,Transgender)in the age group of 20-70 yrs of age. Fasting Plasma Glucose levels in the range of 126-150 mg/dl. Post Prandial Plasma Glucose levels between 200-250 mg/dl. Patients having ALT,AST,Sr.Creatinine, Blood Urea with normal limits. Patients ready to participate in the study and willing to follow the instructions.

Exclusion criteria

Exclusion criteria: Patients with Fasting Plasma Glucose level >150 mg/dl Postprandial Plasma Glucose level >250 mg/dl -Diabetes Mellitus associated with complications of Ketoacidosis Diabetes Mellitus Type-I/ Diabetes Insipidus/ Patients on Insulin therapy Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction Pregnant and lactating women Complications (microangiopathies) associated with longstanding Diabetes like Diabetic Neuropathy, Diabetic Nephropathy and Diabetic Retinopathy Patients having malignancy

Design outcomes

Primary

Measure	Time frame
Glycemic Control in Type 2 Diabetes MellitusTimepoint: 45 days	—

Secondary

Measure	Time frame
Haematological and biochemical Evaluation of SafetyTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Mohammed Sheeraz Mushtaque Ahmed

Regional Research Institute of Unani Medicine (RRIUM)

sheeraz.rrium@gmail.com9797750472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026